Literature DB >> 9148160

Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.

D Schrag1, K M Kuntz, J E Garber, J C Weeks.   

Abstract

BACKGROUND: Women with BRCA1 or BRCA2 mutations have an increased risk of breast cancer and ovarian cancer. Prophylactic mastectomy and oophorectomy are often considered as ways of reducing these risks, but the effect of the procedures on life expectancy has not been established.
METHODS: In a decision analysis, we compared prophylactic mastectomy and prophylactic oophorectomy with no prophylactic surgery among women who carry mutations in the BRCA1 or BRCA2 gene. We used available data about the incidence of cancer, the prognosis for women with cancer, and the efficacy of prophylactic mastectomy and oophorectomy in preventing breast and ovarian cancer to estimate the effects of these interventions on life expectancy among women with different levels of risk of cancer.
RESULTS: We calculated that, on average, 30-year-old women who carry BRCA1 or BRCA2 mutations gain from 2.9 to 5.3 years of life expectancy from prophylactic mastectomy and from 0.3 to 1.7 years of life expectancy from prophylactic oophorectomy, depending on their cumulative risk of cancer. Gains in life expectancy decline with age at the time of prophylactic surgery and are minimal for 60-year-old women. Among 30-year-old women, oophorectomy may be delayed 10 years with little loss of life expectancy.
CONCLUSIONS: On the basis of a range of estimates of the incidence of cancer, prognosis, and efficacy of prophylactic surgery, our model suggests that prophylactic mastectomy provides substantial gains in life expectancy and prophylactic oophorectomy more limited gains for young women with BRCA1 or BRCA2 mutations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9148160     DOI: 10.1056/NEJM199705153362022

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  45 in total

Review 1.  Breast cancer.

Authors:  Monica Morrow; William Gradishar
Journal:  BMJ       Date:  2002-02-16

2.  High frequency of BRCA1/2 germline mutations in 42 Belgian families with a small number of symptomatic subjects.

Authors:  G Goelen; E Teugels; M Bonduelle; B Neyns; J De Grève
Journal:  J Med Genet       Date:  1999-04       Impact factor: 6.318

3.  Acceptance of preventive surgeries by Israeli women who had undergone BRCA testing.

Authors:  Vardit Kram; Tamar Peretz; Michal Sagi
Journal:  Fam Cancer       Date:  2006-05-25       Impact factor: 2.375

4.  American Society of Clinical Oncology policy statement on medicaid reform.

Authors:  Blase N Polite; Jennifer J Griggs; Beverly Moy; Christopher Lathan; Nefertiti C duPont; Gina Villani; Sandra L Wong; Michael T Halpern
Journal:  J Clin Oncol       Date:  2014-11-17       Impact factor: 44.544

5.  Radiation therapy for ductal carcinoma in situ: a decision analysis.

Authors:  Rinaa S Punglia; Harold J Burstein; Jane C Weeks
Journal:  Cancer       Date:  2011-06-30       Impact factor: 6.860

6.  Economic Evaluation Alongside a Clinical Trial of Telephone Versus In-Person Genetic Counseling for BRCA1/2 Mutations in Geographically Underserved Areas.

Authors:  Yaojen Chang; Aimee M Near; Karin M Butler; Amanda Hoeffken; Sandra L Edwards; Antoinette M Stroup; Wendy Kohlmann; Amanda Gammon; Saundra S Buys; Marc D Schwartz; Beth N Peshkin; Anita Y Kinney; Jeanne S Mandelblatt; Yaojen Chang; Aimee M Near; Karin M Butler; Amanda Hoeffken; Sandra L Edwards; Antoinette M Stroup; Wendy Kohlmann; Amanda Gammon; Saundra S Buys; Marc D Schwartz; Beth N Peshkin; Anita Y Kinney; Jeanne S Mandelblatt
Journal:  J Oncol Pract       Date:  2016-01       Impact factor: 3.840

7.  Measuring women's preferences for breast cancer treatments and BRCA1/BRCA2 testing.

Authors:  M Cappelli; L Surh; L Humphreys; S Verma; D Logan; A Hunter; J Allanson
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

8.  Women's views of two interventions designed to assist in the prophylactic oophorectomy decision: a qualitative pilot evaluation.

Authors:  Vanita Bhavnani; Aileen Clarke; Jack Dowie; Andrew Kennedy; Ian Pell
Journal:  Health Expect       Date:  2002-06       Impact factor: 3.377

9.  Distress among women receiving uninformative BRCA1/2 results: 12-month outcomes.

Authors:  Suzanne C O'Neill; Christine Rini; Rachel E Goldsmith; Heiddis Valdimarsdottir; Lawrence H Cohen; Marc D Schwartz
Journal:  Psychooncology       Date:  2009-10       Impact factor: 3.894

10.  Comparison of physicians' and cancer prone women's attitudes about breast/ovarian prophylactic surgery. Results from two national surveys.

Authors:  F Eisinger; D Stoppa-Lyonnet; C Lasset; P Vennin; F Chabal; C Noguès; J P Moatti; H Sobol; C Julian-Reynier
Journal:  Fam Cancer       Date:  2001       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.